Table 4.

Change in inflammatory markers and 25(OH)D by treatment arm, median (IQR)

Vitamin D3 dose assignment (IU/d)
Time point/variablePlacebo1,0002,0004,000Pa
3 months
No. of participants71677678
25(OH)D (ng/mL)13.7 (7.2–18.6)29.7 (25.6–32.9)34.7 (28.8–41.0)45.9 (39.4–55.2)0.001
IL-6 (pg/mL)2.25 (1.30–3.46)2.53 (1.57–4.16)2.24 (1.29–4.28)1.97 (1.09–3.78)0.42
IL-10 (pg/mL)0.51 (0.47–0.63)0.49 (0.45–0.57)0.52 (0.45–0.59)0.52 (0.45–0.61)0.63
sTNF-R2 (pg/mL)2033.4 (1595.4–2542.1)2061.4 (1670.5–2586.8)2198.6 (1851.0–2632.3)1946.0 (1674.5–2537.9)0.32
CRP (mg/L)2.46 (1.27–4.06)2.21 (0.92–4.70)2.39 (0.75–5.29)1.98 (0.49–5.96)0.98
Δ3 month–baseline
No. of participants71677678
25(OH)D ng/mL−2.3 (−5.4–1.7)10.8 (2.5–18.9)19.2 (11.5–26.2)30.2 (21.5–37.6)<0.001
IL-6 (pg/mL)−0.03 (−0.96–0.88)−0.07 (−1.07–0.93)0.01 (−0.57–0.89)0.08 (−0.61–0.71)0.84
IL-10 (pg/mL)0 (−0.06–0.07)−0.01 (−0.08–0.02)−0.02 (−0.09–0.02)0.00 (−0.06–0.04)0.40
sTNF-R2 (pg/mL)−0.89 (−187.75–160.10)−9.88 (−130.28–149.19)59.16 (−132.66–214.59)13.29 (−137.03–144.32)0.35
CRP (mg/L)−0.05 (−1.13–0.98)0.07 (−0.58–0.86)0.02 (−0.68–1.21)0.03 (−0.68–0.79)0.91

Abbreviations: No., number; IQR, interquartile range.

  • aP value calculated using the Kruskal–Wallis test.